CMChantal M. Morel

Chantal M. Morel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chantal M. Morel has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estimating Economic Costs Associated with Treating Antimicrobial-Resistant Infections in Humans in Malawi

    by Edward B. Masoambeta, Ganizani Nansongole, Luigia Scudeller, Tomislav Kostyanev, Finola Leonard, Fiammetta Bozzani, Eric Umar, Chisomo L. Msefula, Chantal M. Morel, Jobiba Chinkhumba

    Background: Antimicrobial resistance (AMR) poses a significant threat to global health and economic development. In Malawi, the economic costs associated with the treatment of AMR infections remain largely unknown which may hinder resource allocation and policy prioritization. Method: The study used a cross-sectional design and was conducted between September 2023 and January 2025 at three different hospital settings. Data were collected from inpatients with laboratory-confirmed urinary tract infection (UTI) or blood stream infection (BSI). Additional follow-up data were collected from patients for four weeks post discharge. We analyzed patient level data first using descriptive statistics and employed an instrumental variable 2-stage least squares regression to estimate drivers of AMR treatments costs. Results: A total of 610 patients participated in the study. Of these, 45% had AMR-associated resistant infections. Overall, E. coli (43%) followed by P. aeruginosa (22%), K. pneumoniae (14%), and S. aureus (10%) were the most common pathogens. UTI was marginally more common (51%) compared to BSI (49%). BSI had a higher average cost than UTI for patients with both susceptible and resistant infections. On average, a patient spent MK283,815.10 (US$163.71) ranging from zero to MK13,500,000 (US$7786.90). Patients with resistant infections incurred, on average, MK161,785 (US$93.32) more than patients with susceptible infections, largely driven by prolonged hospitalization among other factors. Overall, the direct medical observed costs averaged MK37,165.29 (US$21.44) while direct non-medical observed costs averaged MK61,908.71 (US$35.71). Productivity losses for the patient and guardian(s) were a major observed cost averaging MK160,322.80 (US$92.49). The regression results further showed that having a bank account as a proxy of wealth, non-farm business, longer travel duration, BSI, and K. pneumoniae as the causative pathogens were significantly associated with increased cost burden among the patients. Conclusions: AMR-associated infections impose substantial economic burden on patients and households. Further strengthening of AMR surveillance and stewardship are needed as critical elements of Malawi’s National Action Plan. However, measures should also be taken to mitigate the economic consequences related to AMR, especially for patients who bear the brunt of these costs for lack of financial protection in Malawi’s health system.

  • Open Access

    Before or After the Outbreak? Comparing the Economics of ASF Prevention and Response in European Pig Production

    by Chantal Morel, Edgar García Manzanilla, Emma M. Baxter, João Afonso, Jens Peter Nielsen, L. Guardabassi, Jesper Larsen, Jeroen Dewulf

    African swine fever (ASF) poses a serious economic threat to European pig production, with no vaccines or treatments available. This study consolidates the scattered economic evidence on ASF costs and biosecurity expenditure and applies a benefit-cost framework to assess whether prevention-focused investment is a sound economic strategy relative to outbreak response. A structured literature search across PubMed/MEDLINE, Web of Science, ScienceDirect, CAB Abstracts and EconLit (January 1990–December 2025) screened 1,247 records, of which 34 were retained to parameterise an illustrative expected-value benefit-cost analysis, with all costs converted to 2025 EUR. For a 122-sow reference farm, preventive biosecurity was estimated at €125,750 infrastructure plus €22,051 annual operating costs (€12.37 per pig), whereas an outbreak imposed farm-level losses of approximately €838,000, exceeding 830% of annual profits (€101,000). European simulations for larger industrialised herds suggested per-herd direct costs of €0.9–1.2 million, while government-funded control reached €28.4 million even for a geographically limited wild boar outbreak with no domestic pig infections, alongside export losses from trade bans. At base-case assumptions (10% outbreak probability, 50% prevention effectiveness), the farm-level benefit-cost ratio was 1.21:1, rising to 2.42:1 at 20% probability; the break-even threshold was 41.3% prevention effectiveness. Because farm-level analysis captures only part of total costs—indirect trade losses may reach 29 times direct control costs—the sector-wide case for prevention is substantially stronger. Despite considerable uncertainty, the evidence consistently favours prevention over reactive approaches, suggesting policy should prioritise biosecurity investment, particularly for vulnerable small-scale producers facing the highest per-unit costs and greatest outbreak risk.

  • Open Access

    Estimating Economic Costs Associated with Treating Antimicrobial Resistant Infections in Humans in Malawi

    by Edward Masoambeta, Ganizani Nansongole, Luigia Scudeller, Tomislav Kostyanev, Finola Leonard, Fiammetta Bozzani, Eric Umar, Jobiba Chinkhumba, Chisomo L Msefula, Chantal M Morel

    Background: Antimicrobial resistance (AMR) poses a significant threat to global health and economic development. In Malawi, the economic costs associated with AMR remain largely unknown which may hinder resource allocation and policy prioritization. Method: The study used instrumental variable 2-stage least squares regression to analyze patient level cost data at tertiary and secondary level facilities primarily collected from 610 patients with urinary tract infection (UTI) or blood stream infection (BSI) using a questionnaire. Results: Findings indicate that E. coli (43%) followed by K. pneumoniae (14%), and S. aureus (10%) were common pathogens overall. UTI was common (51%) compared to BSI (49%) yet BSI had a higher average cost than UTI for both susceptible and resistant patient categories. In terms of costs, a patient spent MK283,815.10 (US$163.71) on average as a result of AMR infection. The total cost reached as high as MK13,500,000 (US$7,786.90). Patients with a resistant infection incurred, on average MK161,785 (US$93.32) more than patients whose infection was susceptible, with the additional costs being driven by prolonged hospitalization among other factors. The direct medical costs averaged MK37,165.29 (US$21.44) while direct non-medical costs averaged MK61,908.71 (US$35.71). Productivity losses for the patient and guardian(s) were a major cost averaging MK160,322.80 (US$92.49). The regression results further showed that having a bank account as a proxy of wealth, non-farm business, longer travel duration, BSI, and K. pneumoniae as causing pathogens were significantly associated with increased cost burden among the patients. Conclusions: AMR imposes substantial economic burden on Malawi's health system, with most costs falling on patients. Further strengthening of AMR surveillance and stewardship are needed as critical elements of Malawi’s National Action Plan. However, measures should also be taken to mitigate the economic consequences related to AMR, especially for patients who bear the brunt of these costs for lack of financial protection in Malawi’s health system.

  • Open Access

    Prevalence of Extended-Spectrum β-Lactamase-Producing Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae in Wastewater Effluent in Blantyre, Malawi

    by Edna Ibrahim, Charity Mkwanda, Edward Masoambeta, Luigia Scudeller, Tomislav Kostyanev, Hussein H. Twabi, Yohane K. Diness, Jobiba Chinkhumba, Janelisa Musaya, Rajhab S. Mkakosya, et al.

    Background/Objectives: Wastewater treatment plants (WWTPs) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes, which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp), and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April 2023 and March 2024, and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522), and 10.0% Enc (52/522). Antibiotic susceptibility testing showed the highest resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and the lowest resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates, with the most prevalent phenotype being amoxicillin + clavulanate/cotrimoxazole/doxycycline/ciprofloxacin/gentamicin/azithromycin/ceftriaxone (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic-resistant bacteria from sewage effluent. Therefore, the functionality of WWTPs should be improved to minimize the release of these organisms into the environment.


  • Open Access

    Prevalence of Extended Spectrum β-Lactamase-Producing Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae in Wastewater Effluent in Blantyre, Malawi

    by Edna Ibrahim, Charity Trinity Mkwanda, Edward Masoambeta, Luigia Scudeller, Tomislav Kostyanev, Hussein Hassan Twabi, Yohane K. Diness, Watipaso Kasambala, Jobiba Chinkhumba, Janelisa Musaya, et al.

    Background/Objectives: Wastewater treatment plants (WWTP) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp) and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April, 2023 and March, 2024 and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522) and 10.0% Enc (52/522). Antibiotic susceptibility testing showed higher resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and lower resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates with the most prevalent phenotype as AUG-SXT-DXT-CIP-GM-ATH-CRO (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic resistant bacteria from sewage effluent. Therefore, the functionality of WWTP should be improved to minimize the release of these organisms into the environment.


  • Open Access

    Multisystemic resilience to shocks: a temporal analysis of health, fundamental rights and freedoms, and economic resilience during the first wave of the COVID-19 pandemic in 22 European countries

    by Mia Clausin, Alicia Rieckhoff, Fabrizio Tediosi, Chantal M Morel, Yuliya Kaspiarovich, Nicolas Levrat, Didier Wernli

    Objectives Research on resilience to the COVID-19 pandemic has primarily focused on health system resilience. The purpose of this paper is to: (1) develop a broader understanding of societal resilience to shocks by evaluating resilience in three systems: health, economic and fundamental rights and freedoms and (2) to further operationalise resilience in terms of robustness, resistance and recovery. Settings 22 European countries were selected based on the availability of data in the health, fundamental rights and freedoms, and economic systems during the first wave of the COVID-19 pandemic in early 2020. Design This study uses time series data to assess resilience in health, fundamental rights and freedoms, and economic systems. An overall resilience was estimated, as well as three of its components: robustness, resistance and recovery. Results Six countries exhibited an outlier excess mortality peak compared with the prepandemic period (2015–2019). All countries experienced economic repercussions and implemented diverse measures affecting individual rights and freedoms. Three main groups of countries were identified: (1) high health and high or moderate economic and/or fundamental rights and freedoms resilience, (2) moderate health and fundamental rights and freedoms resilience and (3) low resilience in all three systems. Conclusions The classification of countries into three groups provides valuable insights into the multifaceted nature of multisystemic resilience during the first wave of the COVID-19 pandemic. Our study highlights the importance of considering both health and economic factors when assessing resilience to shocks, as well as the necessity of safeguarding individual rights and freedoms during times of crisis. Such insights can inform policy decisions and aid in the development of targeted strategies to enhance resilience in the face of future challenges.


  • Open Access

    Building a multisystemic understanding of societal resilience to the COVID-19 pandemic

    by Didier Wernli, Mia Clausin, Nino Antulov-Fantulin, John Berezowski, Nikola Biller-Andorno, Karl Blanchet, Lucas Böttcher, Claudine Burton-Jeangros, Gérard Escher, Antoine Flahault, et al.

    The current global systemic crisis reveals how globalised societies are unprepared to face a pandemic. Beyond the dramatic loss of human life, the COVID-19 pandemic has triggered widespread disturbances in health, social, economic, environmental and governance systems in many countries across the world. Resilience describes the capacities of natural and human systems to prevent, react to and recover from shocks. Societal resilience to the current COVID-19 pandemic relates to the ability of societies in maintaining their core functions while minimising the impact of the pandemic and other societal effects. Drawing on the emerging evidence about resilience in health, social, economic, environmental and governance systems, this paper delineates a multisystemic understanding of societal resilience to COVID-19. Such an understanding provides the foundation for an integrated approach to build societal resilience to current and future pandemics.


  • Open Access

    A Complexity Lens on the COVID-19 Pandemic

    by Didier Wernli, Fabrizio Tediosi, Karl Blanchet, Kelley Lee, Chantal Morel, Didier Pittet, Nicolas Levrat, Oran Young